Data from the long-awaited ECOG-ACRIN E2108 trial showed that surgery and radiation to the tumor does not extend overall survival compared with systemic treatment alone in women with stage IV breast cancer.
Etienne Garin, MD, PhD, details how the PROACTIF study was conducted and how Y-90 Glass Microspheres could fill an unmet need for patients with hepatocellular…
Abdulrahman Sinno, MD, highlights key trials that have impacted the treatment paradigm in endometrial and ovarian cancer throughout 2023.
Real-world treatment with zanubrutinib was linked to longer treatment persistence, duration, and time to discontinuation in mantle cell lymphoma.
The database of the phase 1/2 trial of EO2401 in combination with nivolumab with or without bevacizumab in recurrent glioblastoma has locked.
In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.
The current health care economy has driven many employers to self-funding models to offer affordable health care coverage to employees.
In case you missed it, these were the key regulatory decisions made by the FDA in March 2024.
Dana M. Chase, MD, FACOG, discusses the antibody-drug conjugate tisotumab vedotin including its mechanism of action, its accelerated approval for patients with recurrent cervical cancer…
In his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for…
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.
